Equities Analysts Offer Predictions for VRDN Q1 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Viridian Therapeutics in a research note issued to investors on Monday, January 27th. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($0.81) for the quarter. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Leerink Partnrs also issued estimates for Viridian Therapeutics’ Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($1.20) EPS, FY2025 earnings at ($3.74) EPS, FY2026 earnings at ($2.95) EPS, FY2027 earnings at ($1.36) EPS and FY2028 earnings at $1.34 EPS.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.08 million.

Several other brokerages have also weighed in on VRDN. TD Cowen initiated coverage on Viridian Therapeutics in a report on Monday, November 25th. They issued a “buy” rating on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and set a $34.00 target price on shares of Viridian Therapeutics in a research report on Monday, December 16th. Wells Fargo & Company restated an “equal weight” rating and issued a $27.00 price target (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Finally, Royal Bank of Canada boosted their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.70.

Viridian Therapeutics Stock Up 3.3 %

Shares of VRDN opened at $20.08 on Wednesday. Viridian Therapeutics has a fifty-two week low of $11.40 and a fifty-two week high of $27.20. The company’s fifty day moving average is $19.43 and its two-hundred day moving average is $19.40. The firm has a market cap of $1.59 billion, a PE ratio of -4.66 and a beta of 1.13. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04.

Hedge Funds Weigh In On Viridian Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in VRDN. FMR LLC increased its holdings in Viridian Therapeutics by 16.8% in the third quarter. FMR LLC now owns 11,183,478 shares of the company’s stock valued at $254,424,000 after buying an additional 1,610,130 shares during the last quarter. Novo Holdings A S raised its stake in Viridian Therapeutics by 19.3% during the third quarter. Novo Holdings A S now owns 2,385,000 shares of the company’s stock worth $54,259,000 after acquiring an additional 385,000 shares during the period. Geode Capital Management LLC lifted its holdings in Viridian Therapeutics by 5.8% in the third quarter. Geode Capital Management LLC now owns 1,493,311 shares of the company’s stock worth $33,979,000 after acquiring an additional 81,951 shares during the last quarter. Great Point Partners LLC boosted its stake in Viridian Therapeutics by 50.0% in the third quarter. Great Point Partners LLC now owns 750,000 shares of the company’s stock valued at $17,062,000 after acquiring an additional 250,000 shares during the period. Finally, Walleye Capital LLC grew its holdings in shares of Viridian Therapeutics by 30.1% during the third quarter. Walleye Capital LLC now owns 560,007 shares of the company’s stock valued at $12,740,000 after purchasing an additional 129,411 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.